JPRN-UMIN000019162已完成4 期
The examination about pharmacokinetics of Tazobactam/Piperacillin [2.25g*2times/day] in the patients who have the blood purification therapy - The examination about pharmacokinetics of Tazobactam/Piperacillin [2.25g*2times/day] in the patients who have the blood purification therapy
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The patients who don't have continuous hemodiafilltration therapy The patients who don't take Tazobactam / Piperacillin
研究者
相似试验
进行中（未招募）
不适用
AObese patients with an infection treated by broad spectrum B-lactams.MedDRA version: 14.1Level: PTClassification code 10060945Term: Bacterial infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-000652-18-BEHopital Erasme
尚未招募
不适用
Blood levels of antitubercular drugs in TB patients associated with diabetes mellitusCTRI/2021/08/035578Maulana Azad Medical College
尚未招募
4 期
Pharmacokinetic study of oral tacrolimus suspensioCTRI/2021/03/031911Indian Council of Medical Research ICMR
进行中（未招募）
不适用
Pharmacokinetics and Tolerability of AV104 (Nalmefene hydrochloride) buccal films in Cholestatic Liver Disease Subjects.CTRI/2022/05/042461Avior Bio Inc
已完成
不适用
Supralimus-Core(TM) Pharmacokinetic(PK) StudyCTRI/2009/091/000426Sahajanand Medical Technologies Pvt Ltd20